Barriers to Uptake of Insulin Technologies and Novel Solutions

Meghan E Pauley, Cari Berget, Laurel H Messer, Gregory P Forlenza Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USACorrespondence: Gregory P ForlenzaBarbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pauley ME, Berget C, Messer LH, Forlenza GP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	type 1 diabetes artificial pancreas insulin pump continuous glucose monitor hybrid closed loop Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/e0e0191288644414a4b7a3de1a62d4e8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e0e0191288644414a4b7a3de1a62d4e8
record_format	dspace
spelling	oai:doaj.org-article:e0e0191288644414a4b7a3de1a62d4e82021-12-02T19:33:20ZBarriers to Uptake of Insulin Technologies and Novel Solutions1179-1470https://doaj.org/article/e0e0191288644414a4b7a3de1a62d4e82021-11-01T00:00:00Zhttps://www.dovepress.com/barriers-to-uptake-of-insulin-technologies-and-novel-solutions-peer-reviewed-fulltext-article-MDERhttps://doaj.org/toc/1179-1470Meghan E Pauley, Cari Berget, Laurel H Messer, Gregory P Forlenza Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USACorrespondence: Gregory P ForlenzaBarbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, 1775 Aurora CT, MS A140, Aurora, CO, 80045, USATel +1 303-724-2323Fax +1 303-724-6779Email gregory.forlenza@cuanschutz.eduAbstract: Diabetes-related technology has undergone great advancement in recent years. These technological devices are more commonly utilized in the type 1 diabetes population, which requires insulin as the primary treatment modality. Available devices include insulin pumps, continuous glucose monitors, and hybrid systems referred to as automated insulin delivery systems or hybrid closed-loop systems, which combine those two devices along with software algorithms to achieve advanced therapeutic capabilities, including automatic modulation of insulin delivery based on sensor-derived glucose levels to minimize abnormal glucose trends. Use of diabetes technology is associated with significant positive health and psychosocial outcomes, yet utilization rates are generally lacking across both adult and pediatric type 1 diabetes populations in the United States and other countries. There are consistent themes in existing barriers to technology uptake reported by individuals with type 1 diabetes or parents of children with type 1 diabetes, including physical burdens associated with wearing the devices, concerns in navigating the technology and the devices’ abilities to meet user expectations, high cost, inadequate resources within the healthcare team to support device use, disparities in technology access, and psychosocial barriers. It is important to understand the common barriers to uptake of not only the automated insulin delivery systems but also their component devices (insulin pumps and continuous glucose monitors) to fully support individuals in utilizing these devices and optimizing health benefits. The purpose of this article is to summarize the current automated insulin delivery devices that are available for use in management of type 1 diabetes, review common barriers to uptake of those systems and their component devices, and provide expert opinion on existing and future solutions to identified barriers.Keywords: type 1 diabetes, artificial pancreas, insulin pump, continuous glucose monitor, hybrid closed loopPauley MEBerget CMesser LHForlenza GPDove Medical Pressarticletype 1 diabetesartificial pancreasinsulin pumpcontinuous glucose monitorhybrid closed loopMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol Volume 14, Pp 339-354 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 1 diabetes artificial pancreas insulin pump continuous glucose monitor hybrid closed loop Medical technology R855-855.5
spellingShingle	type 1 diabetes artificial pancreas insulin pump continuous glucose monitor hybrid closed loop Medical technology R855-855.5 Pauley ME Berget C Messer LH Forlenza GP Barriers to Uptake of Insulin Technologies and Novel Solutions
description	Meghan E Pauley, Cari Berget, Laurel H Messer, Gregory P Forlenza Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USACorrespondence: Gregory P ForlenzaBarbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, 1775 Aurora CT, MS A140, Aurora, CO, 80045, USATel +1 303-724-2323Fax +1 303-724-6779Email gregory.forlenza@cuanschutz.eduAbstract: Diabetes-related technology has undergone great advancement in recent years. These technological devices are more commonly utilized in the type 1 diabetes population, which requires insulin as the primary treatment modality. Available devices include insulin pumps, continuous glucose monitors, and hybrid systems referred to as automated insulin delivery systems or hybrid closed-loop systems, which combine those two devices along with software algorithms to achieve advanced therapeutic capabilities, including automatic modulation of insulin delivery based on sensor-derived glucose levels to minimize abnormal glucose trends. Use of diabetes technology is associated with significant positive health and psychosocial outcomes, yet utilization rates are generally lacking across both adult and pediatric type 1 diabetes populations in the United States and other countries. There are consistent themes in existing barriers to technology uptake reported by individuals with type 1 diabetes or parents of children with type 1 diabetes, including physical burdens associated with wearing the devices, concerns in navigating the technology and the devices’ abilities to meet user expectations, high cost, inadequate resources within the healthcare team to support device use, disparities in technology access, and psychosocial barriers. It is important to understand the common barriers to uptake of not only the automated insulin delivery systems but also their component devices (insulin pumps and continuous glucose monitors) to fully support individuals in utilizing these devices and optimizing health benefits. The purpose of this article is to summarize the current automated insulin delivery devices that are available for use in management of type 1 diabetes, review common barriers to uptake of those systems and their component devices, and provide expert opinion on existing and future solutions to identified barriers.Keywords: type 1 diabetes, artificial pancreas, insulin pump, continuous glucose monitor, hybrid closed loop
format	article
author	Pauley ME Berget C Messer LH Forlenza GP
author_facet	Pauley ME Berget C Messer LH Forlenza GP
author_sort	Pauley ME
title	Barriers to Uptake of Insulin Technologies and Novel Solutions
title_short	Barriers to Uptake of Insulin Technologies and Novel Solutions
title_full	Barriers to Uptake of Insulin Technologies and Novel Solutions
title_fullStr	Barriers to Uptake of Insulin Technologies and Novel Solutions
title_full_unstemmed	Barriers to Uptake of Insulin Technologies and Novel Solutions
title_sort	barriers to uptake of insulin technologies and novel solutions
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/e0e0191288644414a4b7a3de1a62d4e8
work_keys_str_mv	AT pauleyme barrierstouptakeofinsulintechnologiesandnovelsolutions AT bergetc barrierstouptakeofinsulintechnologiesandnovelsolutions AT messerlh barrierstouptakeofinsulintechnologiesandnovelsolutions AT forlenzagp barrierstouptakeofinsulintechnologiesandnovelsolutions
_version_	1718376410856292352

Barriers to Uptake of Insulin Technologies and Novel Solutions

Ejemplares similares